1. "2017"
  2. "Myeloma"
Formats
  1. Journal Article (39)
  2. Meeting Abstract (27)
  3. Book Section (1)
Groups
  1. Center for Hematologic Malignancies (67)
  2. Department of Medicine (67)
  3. Hematologic Malignancies, Division of (67)
  4. Myeloma (67)
  5. Hematologic Malignancies Research (54)
  6. Survivorship Research (23)

More Groups

People
  1. Carl Landgren (44)
  2. Sham Mailankody (24)
  3. Alexander Lesokhin (18)
  4. Hani Hassoun (16)
  5. Neha Korde (16)
  6. Sergio Giralt (16)

More People

Years
  1. 2017 (67)
Publications
  1. Blood (16)
  2. Blood Advances (5)
  3. Haematologica (5)
  4. Leukemia and Lymphoma (5)
  5. Clinical Lymphoma, Myeloma and Leukemia (3)
  6. Biology of Blood and Marrow Transplantation (2)

More Publications

Publishers
  1. American Society of Hematology (22)
  2. Nature Publishing Group (6)
  3. Elsevier Inc. (5)
  4. Ferrata Storti Foundation (5)
  5. Taylor & Francis Group (5)
  6. American Medical Association (4)

More Publishers

Results (67)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Costs and in-hospital mortality rates in autologous stem cell transplant for multiple myeloma: An analysis of the Nationwide Inpatient Sample (NIS) Database
    Meeting Abstract

    Liu, Y.; Han, H.; Wei, X.; Wang, Q.; He, J.; Shah, G. L.; Giralt, S. A.; Landgren, O.; Lesokhin, A.
    Blood (2017)

    Fulltext@MSK | Save
  • MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mailankody, S.; Smith, E. L.; Lendvai, N.; Hassoun, H.; Lesokhin, A.; Hultcrantz, M.; Chung, D. J.; Shah, G. L.; Koehne, G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for BCMA directed therapies
    Meeting Abstract

    Khattar, P.; Pichardo, J.; Jungbluth, A.; Gao, Q.; Smith, E. L.; Roshal, M.; Dogan, A.
    Blood (2017)

    Fulltext@MSK | Save
  • Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after multiple myeloma: Assessment of risk factors
    Meeting Abstract

    Jonsdottir, G.; Bjorkholm, M.; Turesson, I.; Hultcrantz, M.; Porwit, A.; Jethava, Y.; Landgren, O.; Kristinsson, S. Y.
    Blood (2017)

    Fulltext@MSK | Save
  • Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study
    Meeting Abstract

    Hofmeister, C. C.; Chari, A.; Cohen, Y.; Spencer, A.; Voorhees, P. M.; Estell, J.; Venner, C. P.; Sandhu, I.; Jenner, M. W.; Williams, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Development of JCARH125: Optimization of a fully human anti-BCMA CAR for use in the treatment of multiple myeloma
    Meeting Abstract

    Harrington, K.; Wu, R.; Hauskins, C.; Amin, R.; Long, T.; Chen, A.; Rahardjo, A.; Thayer, C.; Navvaro, G.; Myers, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Clinical and pathological features of B-cell acute lymphoblastic leukemia following maintenance treatment with lenalidomide for multiple myeloma
    Meeting Abstract

    Geyer, M. B.; Shaffer, B. C.; Landau, H.; Hassoun, H.; Famulare, C.; Roshal, M.; Dogan, A.; Arcila, M. E.; Park, J. H.
    Blood (2017)

    Fulltext@MSK | Save
  • High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL
    Meeting Abstract

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Next generation sequencing (NGS) based IGH and TCR clonality assays provide excellent specificity and sensitivity for routine clonal characterization and monitoring of lymphoproliferative disorders
    Meeting Abstract

    Arcila, M. E.; Syed, M.; Yu, W.; Kim, H.; Yao, J.; Ho, C.; Petrova-Drus, K.; Roshal, M.; Park, J. H.; Landgren, O.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 "do not eat" signal, induces objective responses in patients with advanced, relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Ansell, S. M.; Flinn, I. W.; Maris, M. B.; O'Connor, O. A.; Lesokhin, A.; Advani, A. S.; Minden, M. D.; Percival, M. B. M.; Johnson, L. D. S.; Catalano, T.; more...
    Blood (2017)

    Fulltext@MSK | Save